Skip to main content

Sanofi-Aventis S.A. ADR(SNY-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Sanofi-Aventis S.A. ADR

46 AVENUE DE LA GRANDE ARMEE
PARIS I0 75017
P: 33-1-53-77-44-00
F: +33 153774303
http://www.sanofi.com

Profile

Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.

Key Executives

NameTitle
Olivier CharmeilExecutive VP, Divisional
Paul HudsonCEO/Director
Jean-Baptiste Chasseloup De ChatillonCFO/Executive VP
Natalie BickfordExecutive VP/Other Executive Officer
Julie Van OngevalleExecutive VP, Divisional
Thomas TriompheExecutive VP, Divisional
Brendan O'CallaghanExecutive VP, Divisional
Roy PapatheodorouExecutive VP/General Counsel
Madeleine RoachExecutive VP, Divisional
Emmanuel FrenehardExecutive VP/Other Executive Officer
Brian FoardExecutive VP, Divisional
Houman AshrafianExecutive VP/Other Corporate Officer